Picture of Britannia Life Sciences logo

BLAB Britannia Life Sciences Cashflow Statement

0.000.00%
ca flag iconLast trade - 00:00
Consumer DefensivesSpeculativeMicro CapContrarian

Annual cashflow statement for Britannia Life Sciences, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.

2020
November 30th
2022
March 31st
2023
March 31st
2024
March 31st
2025
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-3.2-145.84-4.4-4.56
Depreciation
Deferred Taxes
Non-Cash Items2.1816.1-4.455.340.81
Discontinued Operations
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital0.750.461-0.4150.8851.07
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-0.2072.81.222.09-2.62
Capital Expenditures0-0.087-0.342-0.337
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items0.741-2.98-1.111.3
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities00.654-3.32-1.4411.3
Financing Cash Flow Items1.93-0.5960-1.8-1.79
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities0.022-2.582.95-1.97-2.17
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-0.1850.8030.967-1.286.53